ArticleJournal of fluorescence2025
Ofloxacin-Mediated Fluorescence Enhancement of Carbon Quantum Dots for Sensitive and Selective Detection in Pharmaceutical Analysis.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- TiMikrochimica acta · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study introduces an innovative fluorescence enhancement strategy utilizing carbon quantum dots (CQDs) for the ultrasensitive and selective detection of Ofloxacin in pharmaceutical formulations. Synthesized hydrothermally from ascorbic acid, a green, non-toxic precursor, the CQDs exhibit a unique "turn-on" response upon interaction with Ofloxacin, contrasting conventional quenching-based mechanisms. The fluorescence enhancement (22.4% quantum yield) arises from Ofloxacin-induced surface passivation of CQDs, which reduces non-radiative decay pathways, as evidenced by lifetime studies and spectroscopic characterization. Optimized synthesis conditions (180 °C, 8 h) yielded monodisperse CQDs (17-30 nm) with tailored optical properties, validated via TEM, FTIR, XPS, and XRD. Under optimal detection parameters (pH 8.0, 40 °C, 800 µL CQDs), the method achieved a wide linear dynamic range of 0.5-120 µM (y = 0.0186x + 1.0023, R
Indexed as
Identifiers
40613974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.